Critical Limb Ischemia - Pipeline Review, H1 2018

  • ID: 4473289
  • Drug Pipelines
  • 132 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • AnGes MG Inc
  • BiogenCell Ltd
  • Hemostemix Inc
  • Juventas Therapeutics Inc
  • Neurofx Inc
  • Rexgenero Ltd
  • MORE
Critical Limb Ischemia - Pipeline Review, H1 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Critical Limb Ischemia - Pipeline Review, H1 2018, provides an overview of the Critical Limb Ischemia (Cardiovascular) pipeline landscape.

Critical limb ischemia (CLI) is the most severe form of peripheral arterial disease (PAD). It is caused by chronic inflammatory processes associated with atherosclerosis that result in reduced blood flow to the legs, feet and hands. Symptoms include pain or numbness in feet or toes, sores, skin infections will not heal. Treatment goals for CLI include reducing the number of cardiovascular risk factors (such as quitting smoking and reduction of cholesterol), relieving pain, healing ulcers, preventing major amputation, improving quality of life and increasing survival.

Report Highlights:

Pharmaceutical and Healthcare latest pipeline guide Critical Limb Ischemia - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Critical Limb Ischemia (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Critical Limb Ischemia (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Critical Limb Ischemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed and Preclinical stages are 1, 2, 17, 2, 1 and 11 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Critical Limb Ischemia (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Critical Limb Ischemia (Cardiovascular).
  • The pipeline guide reviews pipeline therapeutics for Critical Limb Ischemia (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Critical Limb Ischemia (Cardiovascular) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Critical Limb Ischemia (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Critical Limb Ischemia (Cardiovascular)
Reasons to buy:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Critical Limb Ischemia (Cardiovascular).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Critical Limb Ischemia (Cardiovascular) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • AnGes MG Inc
  • BiogenCell Ltd
  • Hemostemix Inc
  • Juventas Therapeutics Inc
  • Neurofx Inc
  • Rexgenero Ltd
  • MORE
Introduction

Report Coverage

Critical Limb Ischemia - Overview

Critical Limb Ischemia - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Critical Limb Ischemia - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Critical Limb Ischemia - Companies Involved in Therapeutics Development

AnGes MG Inc

apceth Biopharma GmbH

Athersys Inc

BiogenCell Ltd

Caladrius Biosciences Inc

Cynata Therapeutics Ltd

Hemostemix Inc

Histocell SL

ID Pharma Co Ltd

Integene International Holdings LLC

Juventas Therapeutics Inc

Kang Stem Biotech Co Ltd

Kasiak Research Pvt Ltd

Neurofx Inc

Nissan Chemical Industries Ltd

Pharmicell Co Ltd

Pluristem Therapeutics Inc

ReNeuron Group Plc

Rexgenero Ltd

Symic Biomedical Inc

TaiGen Biotechnology Co Ltd

TikoMed AB

U.S. Stem Cell Inc

VESSL Therapeutics Ltd

ViroMed Co Ltd

YiChang Humanwell Pharmaceutical Co Ltd

Critical Limb Ischemia - Drug Profiles

ACP-01 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AdipoCell - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Alecmestencel-T - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ASCT-01 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

beperminogene perplasmid - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BGC-101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Biologic to Activate FGF2 for Critical Limb Ischemia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

burixafor - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cell Therapy for Peripheral Arterial Disease and Coronary Artery Diseases - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cellgram-CLI - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CLBS-12 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

donaperminogene seltoplasmid - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DVC-10101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy for Critical Limb Ischemia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy to Activate HGF for Critical Limb Ischemia and Chronic Post-Operative Pain - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HC-016 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

JVS-100 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NFx-101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NK-104 NP - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PF-05285401 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PLX-PAD - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Procell - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Protein to Agonize LRP5 and LRP6 for Critical Limb Ischemia and Myocardial Infarction - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Refacell-CLI - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Rejuveinix - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ReN-009 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

REX-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

REX-002 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

REX-003 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SB-030 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Stem Cell Therapy for Cardiovacular Diseases and Asthma - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Stem Cell Therapy for Critical Limb Ischemia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Stem Cell Therapy for Critical Limb Ischemia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TM-700 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TXA-302 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Critical Limb Ischemia - Dormant Projects

Critical Limb Ischemia - Discontinued Products

Critical Limb Ischemia - Product Development Milestones

Featured News & Press Releases

Jan 30, 2018: EMA grants Rexgenero’s lead product REX-001 Advanced Therapy Medicinal Product Certificate for Manufacturing Quality and Non-Clinical Data

Jan 25, 2018: Rexgenero treats first patient in its Phase III programme with lead product REX-001, a novel cell therapy for the treatment of Critical Limb Ischemia (CLI)

Jan 22, 2018: AnGes Submits Application for Marketing Approval to PMDA for HGF gene therapy for Critical Limb Ischemia

Jan 09, 2018: FDA Clears Pluristem’s Expanded Access Program to Initiate Treatments of Critical Limb Ischemia Outside of Ongoing Phase III Study

Dec 20, 2017: Hemostemix Receives Health Canada Clearance to Continue with Critical Limb Ischemia Clinical Trials

Dec 12, 2017: Pluristem Granted Manufacturer Authorization and Good Manufacturing Practice (GMP) Certification by Israel’s Ministry of Health, Supporting Pivotal-Stage Studies

Oct 09, 2017: BioTech Identifies and Files Patent on ProCell Mechanism of Action in Saving Limbs from Amputation

Oct 02, 2017: $7.9 Million Granted to nTRACK Collaborative Project Designed to Study Pluristem’s PLX-PAD Cells

Sep 27, 2017: U.S. Patent Granted for Cynata Cymerus Technology

Sep 26, 2017: Hemostemix Announces Agreement with CRO Service Provider Topstone Research

Sep 18, 2017: U.S. FDA Grants Fast Track Designation to Pluristem's PLX-PAD for the Treatment of Critical Limb Ischemia

Sep 07, 2017: Caladrius Biosciences to Participate at Upcoming September Conferences

Sep 05, 2017: Cynata to Present at the 19th Annual Rodman & Renshaw Global Investment Conference in New York

Jul 10, 2017: Pluristem Advances its Multinational Phase III Critical Limb Ischemia Study, Targeting Initiation at 40 Active Sites by the End of 2017

Jan 23, 2017: Consortium including TrakCel awarded £1.4 million from Innovate UK for commercialisation of Rexgenero cell therapy

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables:

Number of Products under Development for Critical Limb Ischemia, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Products under Development by Universities/Institutes, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Critical Limb Ischemia - Pipeline by AnGes MG Inc, H1 2018

Critical Limb Ischemia - Pipeline by apceth Biopharma GmbH, H1 2018

Critical Limb Ischemia - Pipeline by Athersys Inc, H1 2018

Critical Limb Ischemia - Pipeline by BiogenCell Ltd, H1 2018

Critical Limb Ischemia - Pipeline by Caladrius Biosciences Inc, H1 2018

Critical Limb Ischemia - Pipeline by Cynata Therapeutics Ltd, H1 2018

Critical Limb Ischemia - Pipeline by Hemostemix Inc, H1 2018

Critical Limb Ischemia - Pipeline by Histocell SL, H1 2018

Critical Limb Ischemia - Pipeline by ID Pharma Co Ltd, H1 2018

Critical Limb Ischemia - Pipeline by Integene International Holdings LLC, H1 2018

Critical Limb Ischemia - Pipeline by Juventas Therapeutics Inc, H1 2018

Critical Limb Ischemia - Pipeline by Kang Stem Biotech Co Ltd, H1 2018

Critical Limb Ischemia - Pipeline by Kasiak Research Pvt Ltd, H1 2018

Critical Limb Ischemia - Pipeline by Neurofx Inc, H1 2018

Critical Limb Ischemia - Pipeline by Nissan Chemical Industries Ltd, H1 2018

Critical Limb Ischemia - Pipeline by Pharmicell Co Ltd, H1 2018

Critical Limb Ischemia - Pipeline by Pluristem Therapeutics Inc, H1 2018

Critical Limb Ischemia - Pipeline by ReNeuron Group Plc, H1 2018

Critical Limb Ischemia - Pipeline by Rexgenero Ltd, H1 2018

Critical Limb Ischemia - Pipeline by Symic Biomedical Inc, H1 2018

Critical Limb Ischemia - Pipeline by TaiGen Biotechnology Co Ltd, H1 2018

Critical Limb Ischemia - Pipeline by TikoMed AB, H1 2018

Critical Limb Ischemia - Pipeline by U.S. Stem Cell Inc, H1 2018

Critical Limb Ischemia - Pipeline by VESSL Therapeutics Ltd, H1 2018

Critical Limb Ischemia - Pipeline by ViroMed Co Ltd, H1 2018

Critical Limb Ischemia - Pipeline by YiChang Humanwell Pharmaceutical Co Ltd, H1 2018

Critical Limb Ischemia - Dormant Projects, H1 2018

Critical Limb Ischemia - Dormant Projects, H1 2018 (Contd..1), H1 2018

Critical Limb Ischemia - Discontinued Products, H1 2018

List of Figures:

Number of Products under Development for Critical Limb Ischemia, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products by Targets, H1 2018

Number of Products by Stage and Targets, H1 2018

Number of Products by Mechanism of Actions, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • AnGes MG Inc
  • apceth Biopharma GmbH
  • Athersys Inc
  • BiogenCell Ltd
  • Caladrius Biosciences Inc
  • Cynata Therapeutics Ltd
  • Hemostemix Inc
  • Histocell SL
  • ID Pharma Co Ltd
  • Integene International Holdings LLC
  • Juventas Therapeutics Inc
  • Kang Stem Biotech Co Ltd
  • Kasiak Research Pvt Ltd
  • Neurofx Inc
  • Nissan Chemical Industries Ltd
  • Pharmicell Co Ltd
  • Pluristem Therapeutics Inc
  • ReNeuron Group Plc
  • Rexgenero Ltd
  • Symic Biomedical Inc
  • TaiGen Biotechnology Co Ltd
  • TikoMed AB
  • U.S. Stem Cell Inc
  • VESSL Therapeutics Ltd
  • ViroMed Co Ltd
  • YiChang Humanwell Pharmaceutical Co Ltd
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll